EVAX

Evaxion A/S ADR

3.03

Oct 30 • 11:32 AM ET -0.05 (-1.62%)

Healthcare Biotechnology Denmark Nano NASD

Peers: ELTX BNTX ANIX INO PDSB ABSI MRNA PCVX RXRX GOVX

Index	-
Market Cap	25.27M
Enterprise Value	18.37M
Income	-8.68M
Sales	7.46M
Book/sh	1.14
Cash/sh	1.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	46
IPO	Feb 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	3.39
P/B	2.65
P/C	1.81
P/FCF	-
EV/EBITDA	-
EV/Sales	2.46
Quick Ratio	5.06
Current Ratio	5.06
Debt/Eq	0.75
LT Debt/Eq	0.69
Option/Short	No / Yes

EPS (ttm)	-1.05
EPS next Y	-0.01
EPS next Q	-0.01
EPS this Y	-100.00%
EPS next Y	62.50%
EPS next 5Y	-
EPS past 3/5Y	70.92% 51.86%
Sales past 3/5Y	- -
EPS Y/Y TTM	82.33%
Sales Y/Y TTM	134.15%
EPS Q/Q	42.42%
Sales Q/Q	-100.00%
Earnings	Nov 19 BMO
EPS/Sales Surpr.	0.00% -

Insider Own	19.22%
Insider Trans	0.00%
Inst Own	6.17%
Inst Trans	0.69%
ROA	-41.51%
ROE	-110.21%
ROIC	-53.95%
Gross Margin	-
Oper. Margin	-116.83%
Profit Margin	-116.42%
SMA20	-4.84%
SMA50	-4.86%
SMA200	-13.47%
Trades

Shs Outstand	8.34M
Shs Float	6.74M
Short Float	0.99%
Short Ratio	0.29
Short Interest	0.07M
52W High	6.92 -56.21%
52W Low	2.72 11.40%
Volatility	11.96% 9.45%
ATR (14)	0.30
RSI (14)	45.17
Beta	0.61
Rel Volume	0.22
Avg Volume	230.76K
Volume	18,418

Perf Week	-19.41%
Perf Month	-4.72%
Perf Quarter	8.60%
Perf Half Y	-32.59%
Perf YTD	-36.48%
Perf Year	-47.40%
Perf 3Y	-93.52%
Perf 5Y	-99.20%
Perf 10Y	-
Recom	1.00
Target Price	12.25
Prev Close	3.08
Price	3.03
Change %	-1.62%

Consensus

Strong Buy

Avg. Price Target

$12.25

Implied Upside

+304.3%

Analysts3incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Feb 19, 2026	Initiated	MMaxim Group	Buy	$10	+230.0%
Apr 02, 2024	Upgrade	LLadenburg Thalmann	Neutral → Buy	$8	+164.0%
Feb 12, 2024	Initiated	HH.C. Wainwright	Buy	$14	+362.0%

Today 04:00AM	Evaxion receives International Prix Galien Award for AI-Immunology as best digital health solution (GlobeNewswire)
Oct-23-26 07:15AM	EVAX Stock Heads For Best Week Since January 2025 As Cancer Vaccine Shows 89% Target Precision (Stocktwits)
02:00AM	Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 (GlobeNewswire)
Oct-19-26 12:58PM	Evaxion stock surges on 3-year melanoma vaccine trial data (Investing.com) +17.67%
06:27AM	INTC, EVAX, RCAT Stocks Move Higher Premarket Whats Driving The Rally? (Stocktwits)
03:00AM	Loading…
03:00AM	Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 (GlobeNewswire)
Oct-02-26 09:00AM	Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting (GlobeNewswire)
Sep-14-26 08:00AM	Evaxion applies its AI-Immunology platform in autoimmune diseases (GlobeNewswire)
Aug-20-26 07:01PM	Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ... (GuruFocus.com)
07:30AM	Evaxion announces business update and second quarter 2026 financial results (GlobeNewswire)
Aug-17-26 08:00AM	Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program (GlobeNewswire) -6.29%
Aug-14-26 08:00AM	Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 (GlobeNewswire)
Jul-17-26 07:15AM	Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 (GlobeNewswire)
Jul-12-26 09:30AM	Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 (GlobeNewswire)
Jul-01-26 08:00AM	Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop (GlobeNewswire)
03:00AM	Loading…
Jun-12-26 03:00AM	Evaxion receives Prix Galien UK Award for Best digital health solution (GlobeNewswire)
Jun-11-26 02:00AM	Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (GlobeNewswire)
May-12-26 09:30AM	Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress (GlobeNewswire)
May-07-26 07:30AM	Evaxion announces business update and first quarter 2026 financial results (GlobeNewswire) -7.71%
May-04-26 08:00AM	Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 (GlobeNewswire)
Apr-27-26 08:00AM	Evaxion promotes Birgitte Rono to joint role of Chief Scientific and Chief Operating Officer (GlobeNewswire)
Apr-17-26 03:10PM	Evaxion's AI-Immunology platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial (GlobeNewswire) +7.49%
03:00PM	New data demonstrates the unique scalability of Evaxion's AI-Immunology platform in glioblastoma (GlobeNewswire)
Apr-16-26 11:30AM	Evaxion concludes Annual General Meeting (GlobeNewswire)
Apr-07-26 08:00AM	Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 (GlobeNewswire)
Mar-30-26 08:00AM	Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress (GlobeNewswire) +7.10%
Mar-19-26 09:00AM	Notice to convene Evaxion's Annual General Meeting (GlobeNewswire) +5.82%
Mar-17-26 04:30PM	Evaxion to present new data at AACR Annual Meeting (GlobeNewswire)
Mar-09-26 09:06PM	Evaxion AS (EVAX) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial Resilience (GuruFocus.com) +16.23%
09:03PM	Evaxion AS (EVAX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
09:28AM	Loading…
Mar-05-26 09:28AM	Evaxion announces business update and full year 2025 financial results (GlobeNewswire) +9.32%
08:02AM	Evaxion plans to file 2025 annual report later today (GlobeNewswire)
Mar-02-26 08:00AM	Evaxion to announce business update and full year 2025 financial results on March 5, 2026 (GlobeNewswire)
Jan-13-26 08:00AM	Evaxion expands AI-Immunology platform into autoimmune diseases (GlobeNewswire)
Jan-07-26 08:00AM	Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week (GlobeNewswire) +6.73%
Dec-19-25 07:00AM	Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 (GlobeNewswire) -18.26%
Dec-06-25 02:00PM	Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting (GlobeNewswire)
Nov-20-25 08:00AM	Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 (GlobeNewswire) +9.43%
Nov-12-25 08:00AM	Evaxion announce 2026 financial calendar (GlobeNewswire)
Nov-07-25 05:10PM	Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 (GlobeNewswire)
Nov-06-25 07:30AM	Evaxion announces business update and third quarter 2025 financial results (GlobeNewswire) +10.60%
Nov-03-25 09:00AM	Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate (GlobeNewswire)
Oct-31-25 09:05AM	Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 (GlobeNewswire)
08:00AM	Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	Evaxion raises $7.2 million, extending cash runway to second half of 2027 (GlobeNewswire)
Oct-27-25 08:00AM	Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer (GlobeNewswire)
Oct-26-25 06:05AM	Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data (Insider Monkey)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire) -29.27%
08:15AM	Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 (GlobeNewswire)
Oct-13-25 08:00AM	Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 (GlobeNewswire) +6.10%
Oct-08-25 08:12AM	Evaxion expands AI-Immunology platform with automated vaccine design module (GlobeNewswire) +9.97%
Oct-03-25 09:00AM	Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting (GlobeNewswire) +14.56%
Sep-25-25 12:35PM	MSD pays up to nearly $600m for Evaxions mystery vaccine candidate (Pharmaceutical Technology) +37.27%
07:00AM	Evaxion out-licenses vaccine candidate EVX-B3 to MSD (GlobeNewswire)
Aug-27-25 08:00AM	Evaxion to present at several conferences during the second half of 2025 (GlobeNewswire)
Aug-14-25 07:30AM	Evaxion announces business update and second quarter 2025 financial results (GlobeNewswire) -5.92%
Aug-11-25 08:00AM	Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire)
Jul-25-25 09:00AM	Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 (GlobeNewswire)
Jul-11-25 08:00AM	Evaxion finalizes agreement with EIB to convert debt into equity (GlobeNewswire)
Jul-01-25 08:30AM	Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology platform and portfolio (GlobeNewswire)
Jun-25-25 08:00AM	Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus (GlobeNewswire) +5.71%
Jun-03-25 09:15AM	Evaxion receives grant funding to design new polio vaccine (GlobeNewswire)
May-28-25 03:03AM	Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ... (GuruFocus.com) +11.44%
May-27-25 07:30AM	Evaxion announces business update and first quarter 2025 financial results (GlobeNewswire) +25.53%
May-23-25 08:00AM	Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 (GlobeNewswire)
May-22-25 08:00AM	Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 (GlobeNewswire) +8.09%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
Apr-28-25 08:00AM	80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting (GlobeNewswire)
Apr-10-25 08:00AM	Evaxion to present at World Vaccine Congress (GlobeNewswire)
Apr-02-25 08:56AM	Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement (TipRanks)
03:00AM	Evaxion Biotech AS (EVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
Apr-01-25 11:18PM	Q4 2024 Evaxion Biotech A/S Earnings Call (Thomson Reuters StreetEvents) -10.27%
11:21AM	Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
07:30AM	Evaxion announces business update and full year 2024 financial results (GlobeNewswire)
Mar-27-25 08:00AM	Evaxion to announce business update and full year 2024 financial results on April 1, 2025 (GlobeNewswire)
Mar-25-25 04:30PM	Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting (GlobeNewswire) -5.41%
Mar-04-25 08:00AM	Evaxion to present at numerous upcoming conferences (GlobeNewswire)
Feb-25-25 08:00AM	Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package (GlobeNewswire) -11.07%
Feb-14-25 08:00AM	Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination (GlobeNewswire)
Feb-05-25 08:45AM	Evaxion Biotech price target lowered to $6 from $35 at Lake Street (TipRanks) -8.56%
Jan-31-25 04:05PM	Evaxion announces closing of $10.8 million public offering (GlobeNewswire)
Jan-30-25 08:00AM	Evaxion announces pricing of $10.8 million public offering (GlobeNewswire) -27.14%
Jan-28-25 08:15AM	Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement (GlobeNewswire) -27.17%
Jan-16-25 06:08AM	Evaxion concludes subject dosing in Phase II trial of melanoma vaccine (Clinical Trials Arena)
Jan-15-25 08:00AM	Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 (GlobeNewswire) -12.94%
Jan-14-25 04:05PM	Evaxion announces completion of ADS ratio change (GlobeNewswire) -11.08%
Jan-10-25 08:00AM	Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change (GlobeNewswire)
Dec-30-24 08:00AM	Evaxion announces plan to implement ADS ratio change (GlobeNewswire) -9.63%
Dec-17-24 08:00AM	Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity (GlobeNewswire) -8.92%
Dec-12-24 08:00AM	Evaxion establishes new AI-derived precision cancer vaccine concept (GlobeNewswire) -8.46%
Dec-09-24 08:00AM	Evaxion announces 2025 milestones reflecting continued strong strategy execution (GlobeNewswire)
Dec-02-24 08:00AM	Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress (GlobeNewswire) -7.23%
Nov-13-24 08:00AM	Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing (GlobeNewswire) -26.05%
Nov-12-24 08:00AM	Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 (GlobeNewswire)
Oct-31-24 08:00AM	Evaxion announces business update and third quarter 2024 financial results (GlobeNewswire)
Oct-28-24 08:00AM	Evaxion to announce business update and third quarter 2024 financial results on October 31 (GlobeNewswire)
Oct-09-24 08:00AM	Strong validation of Evaxion's AI-Immunology platform in multiple clinical trials (GlobeNewswire) -5.63%
Oct-04-24 07:27AM	Evaxion Biotech Charts Future with Innovative Immune Therapies (TipRanks)
Oct-03-24 08:00AM	Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology platform (GlobeNewswire)

Show Previous News

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Moller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Ph.D.Dr. Helen Katrina Tayton-Martin MBA

Founder & Chief AI OfficerMr. Andreas Holm Mattsson M.Sc.

Chief Financial OfficerMr. Thomas Frederik Schmidt M.Sc.

Chief Scientific Officer & COODr. Birgitte Rono Ph.D.

Vice President of Clinical DevelopmentMr. Benjamin Ole Wolthers

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVAX

Evaxion A/S ADR

Upgrade your Finviz experience